IMU 8.51% 4.3¢ imugene limited

Ann: Imugene to Present at Annual JPMorgan Healthcare Conference, page-16

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 86 Posts.
    lightbulb Created with Sketch. 395

    I think the JP Morgan conference could be another pivotal point in Imugenes journey, mentioned in the announcement there will be a focus on azer-cel. Personally, I'm hoping for a data cut from the Vaxinia trial and also hints of efficacy from the Azer-cel trial.

    Digging through old Precision slide decks it seems that a lot of their responses whether good or bad have been identified at the 28-day mark. This can be seen below in several of Precisions slides regarding their variation of trials within the azer-cel program.

    https://investor.precisionbiosciences.com/static-files/df1179ae-c2c7-4f88-bb3e-431293fa6ba6

    https://investor.precisionbiosciences.com/static-files/2985f288-57db-476d-ab7c-d33fecc82f57

    Referring to the announcement it appears that the first patient was dosed 54 days ago on November 10th, 2023, I’m sure the process of identifying responses is time consuming and difficult over the break but I would think by now we would be able to see initial data starting to come together. Would love to see Imugene present some clarity around the number of patients currently enrolled and some efficacy around the first patient and their progress.

 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
4.3¢
Change
-0.004(8.51%)
Mkt cap ! $319.8M
Open High Low Value Volume
4.6¢ 4.6¢ 4.3¢ $2.112M 47.68M

Buyers (Bids)

No. Vol. Price($)
40 6781697 4.3¢
 

Sellers (Offers)

Price($) Vol. No.
4.4¢ 315883 2
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.